CNS Pharmaceuticals prices $1.4M registered direct offering and concurrent private placement at $3.75 per share.
CNS Pharmaceuticals, a biopharmaceutical company specializing in brain and central nervous system cancer treatments, announces the pricing of a registered direct offering and a concurrent private placement. Health-care focused institutional investors will purchase 366,000 shares of common stock at $3.75 per share, with warrants to buy 366,000 more shares at $3.62 per share, exercisable immediately and valid for 5 years.
June 14, 2024
5 Articles